Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression role of the glucocorticoid receptor

Circulation

Volumn 104, Issue 23, 2001, Pages 2826-2831

  Herkert, Olaf ^a   Kuhl, Herbert ^a   Sandow, Jurgen ^a   Busse, Rudi ^a   Schini Kerth, Valérie B ^a,b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b CNRS   (France)

Author keywords

Muscle smooth; Progestin; Thrombin; Thrombosis; Tissue factor

Indexed keywords

DEXAMETHASONE; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; NORETHISTERONE; PROCOAGULANT; PROTEINASE ACTIVATED RECEPTOR 1; SEX HORMONE; THROMBIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY WALL; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; HORMONAL THERAPY; NONHUMAN; ORAL CONTRACEPTION; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; THROMBOEMBOLISM; VASCULAR RING; VASCULAR SMOOTH MUSCLE;

EID: 0035808001     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc4801.099737     Document Type: Article

References (30)

1. Risk of venous thronmboembolism in users of hormone replacement therapy
2. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control
3. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease
4. Oral contraceptives estrogen dose and the risk of deep venous thromboembolic disease
5. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: Cohort and case-control analysis
6. Population-based study of risk of venous thromboembolism associated with various oral contraceptives
7. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables
8. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status
9. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives
10. AB
11. L-Arginine evokes both endotheliumdependent and -independent relaxations in L-arginine-depleted aortas of the rat
12. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma: Its inhibition by heparin
13. Serum levels of 3-keto-desogestrel and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 150 μg desogestrel
14. Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 75 μg gestodene
15. Plasma concentrations of medroxyprogesterone acetate, estradiol and estrone following oral administration of Klimaxil®, Trisequence®/Provera® and Divina®: A randomized, single-blind, triple cross-over bioavailability study in menopausal women
16. Progestins stimulate the differentiation of 3T3-LI preadipocytes
17. Binding of progestins to the glucocorticoid receptor: Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes
18. Stimulation of specific transcription and DNA binding studies suggest that in vitro transformed RU 486-glucocorticosteroid receptor complexes display agonist activity
19. 2+ mobilization and protein kinase C activation
20. Tissue factor expression in human arterial smooth muscle cells: TF is present in three cellular pools after growth factor stimulation
21. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
22. Homologous desensitization of HEL cell thrombin receptors: Distinguishable roles for proteolysis and phosphorylation
23. Multivariate preclinical evaluation of progestins
24. Molecular cloning of the rat vascular smooth muscle thrombin receptor: Evidence for in vitro regulation by basic fibroblast growth factor
25. Vascular thrombin receptor regulation in hypertensive rats
26. Regulation of the thrombin receptor response in human endothelial cells
27. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells
28. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide
29. A nuclear binding assay to assess the biological activity of steroid receptors in isolated animal and human tissues
30. Thromboembolic complications, heparin treatment and increase in coagulation factors in Cushing's syndrome